Ross Dubois

RaeSedo Inc., a spin-out of the University of Arizona developing novel therapies for asthma, is pleased to announce the award of a Phase 2 Small Business Technology Transfer (STTR) grant awarding $3.4 million over two years to continue developing potential therapeutics. Founded and led by researchers from the University of Arizona, RaeSedo Inc. moves into this next …

RaeSedo Inc. awarded $3.4M STTR Grant to Develop New Asthma Therapies Read More »

Surfactant Protein-A (SP-A) plays a crucial role in asthma, but genetic variation can lead to dysfunction. Researchers investigated a specific genetic change at position 223 in SP-A2, finding that individuals with the major variant (223Q) had better lung function, reduced inflammation, and improved asthma control. In mouse models and cells from asthmatic participants, they also showed that SP-A 223Q peptides had anti-inflammatory effects, suggesting their potential as therapeutic agents for asthma.

The lung surfactant proteins are recognized as critical not only for their role in lowering lung surface tension but also in innate host defense. Reports have shown that some asthmatic patients have decreased levels of one member of this protein family in particular, surfactant protein-A (SP-A). Our studies set out to determine the contribution of …

Surfactant Protein-A protects against IL-13-induced inflammation in asthma Read More »